BGI Genomics has completed the third phase of its share buyback plan through centralized competitive trading. As of August 5, 2026, the company had repurchased a total of 6.7316 million shares, accounting for 1.61% of the current total share capital, with a total payment of 251 million yuan. The buyback implementation period was from July 13 to August 5, 2026, with the highest transaction price at 40.00 yuan per share and the lowest at 35.33 yuan per share. The actual total funds used exceeded the lower limit of 250 million yuan set in the buyback plan but did not exceed the upper limit of 500 million yuan. The repurchased shares will be used entirely for employee stock ownership plans or equity incentives, and will not carry voting rights or other shareholder rights during the holding period.
BGI Genomics Co LtdCompany completed share buyback, signaling confidence and supporting stock price.
